Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease

doi:10.3748/wjg.v27.i10.959

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 27, Issue 10

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (16549)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-4) series.

Item

Count

PDF

887

WORD

320

HTML

12481

Figures (1-2)

462

Tables (1-4)

367

Sum=14517

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

637

Download

1395

Sum=2032

Mar 14, 2021 (publication date) through Dec 25, 2024

Times Cited of This Article

Times Cited (42)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Gastroenterol. Mar 14, 2021; 27(10): 959-975
Published online Mar 14, 2021. doi: 10.3748/wjg.v27.i10.959

Open in New Tab Full Size Figure Download Figure

Figure 1 Patient enrollment flowchart. NAFLD: Nonalcoholic fatty liver disease; FLI: Fatty liver index; NSAID: Nonsteroidal anti-inflammatory drug.

Open in New Tab Full Size Figure Download Figure

Figure 2 Scheme of the study. UDCA: Ursodeoxycholic acid; NFS: Nonalcoholic fatty liver disease fibrosis score; FIB-4: Liver fibrosis index; FLI: Fatty liver index; CIMT: Carotid intima-media thickness: ASCVD: Atherosclerotic Cardiovascular Disease.

Citation: Nadinskaia M, Maevskaya M, Ivashkin V, Kodzoeva Kh, Pirogova I, Chesnokov E, Nersesov A, Kaibullayeva J, Konysbekova A, Raissova A, Khamrabaeva F, Zueva E. Ursodeoxycholic acid as a means of preventing atherosclerosis, steatosis and liver fibrosis in patients with nonalcoholic fatty liver disease. World J Gastroenterol 2021; 27(10): 959-975
URL: https://www.wjgnet.com/1007-9327/full/v27/i10/959.htm
DOI: https://dx.doi.org/10.3748/wjg.v27.i10.959